CJC-1295+DAC 5mg
(GHRH)

Premium Grade | UK Supply

(Tetrasectide, 44 amino acids)

Brief Summery

CJC-1295+DAC is a modified peptide research compound studied in laboratory settings for its interaction with growth hormone releasing hormone pathways and extended activity profile analysis. It is commonly examined in controlled investigational models focused on receptor signalling, endocrine response patterns, and comparative peptide mechanism research. Within scientific supply catalogues, CJC-1295+DAC is valued for in vitro and preclinical studies involving pathway duration, secretion related marker observation, and structured peptide design investigation. Its role in research centres on analytical evaluation, documented laboratory handling, and consistent experimental planning, making it suitable for professional scientific environments requiring clear, research focused peptide supply standards.

Product Overview

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic peptide analogue of growth hormone–releasing hormone (GHRH), developed to provide prolonged stimulation of endogenous growth hormone secretion. Through the incorporation of a Drug Affinity Complex, CJC-1295 is engineered to reversibly bind to circulating plasma proteins, significantly extending its functional activity compared to native GHRH and shorter-acting analogues. Within research environments, CJC-1295 with DAC is utilised to examine sustained growth hormone signalling, endocrine rhythm modulation, and long-term activation of the GH–IGF-1 axis. Its extended activity profile allows researchers to study continuous hormonal stimulation while maintaining physiological regulation mechanisms, making it a valuable compound for investigations requiring stable and prolonged endocrine engagement. Due to its molecular stability, receptor specificity, and predictable pharmacokinetic profile, CJC-1295 with DAC is widely recognised in peptide research as a specialised tool for exploring growth hormone–mediated metabolic, anabolic, and regulatory processes.

Scientific Background

CJC-1295 is structurally based on growth hormone–releasing hormone, with targeted amino acid substitutions that enhance resistance to enzymatic degradation. The addition of the Drug Affinity Complex enables covalent but reversible binding to serum albumin, dramatically extending the peptide's half-life and allowing sustained interaction with GHRH receptors located on somatotroph cells of the anterior pituitary. Upon receptor activation, CJC-1295 with DAC initiates intracellular signalling pathways involving cyclic AMP (cAMP) and protein kinase A, leading to increased synthesis and pulsatile release of growth hormone. This prolonged stimulation results in elevated and sustained downstream production of insulin-like growth factor-1 (IGF-1), a key mediator of cellular growth, metabolic regulation, and tissue maintenance. Importantly, despite its extended activity, CJC-1295 with DAC preserves endogenous feedback mechanisms. Regulatory control via somatostatin and IGF-1 remains intact, allowing for detailed study of long-term endocrine adaptation, receptor sensitivity, and hormonal homeostasis without forced hormone replacement.

Research Applications

CJC-1295 with DAC is extensively researched in endocrinology and metabolic science, particularly in studies examining prolonged growth hormone exposure and its systemic effects. Researchers utilise this peptide to investigate sustained GH–IGF-1 signalling, endocrine rhythm stability, and the physiological impact of extended hormone release patterns. In metabolic research, CJC-1295 with DAC is explored for its role in lipid metabolism regulation, energy utilisation pathways, and nutrient partitioning, all of which are closely linked to growth hormone activity. Its long-acting profile makes it especially suitable for experimental models requiring consistent hormonal signalling over extended periods. Additionally, CJC-1295 with DAC is used in studies focused on cellular regeneration, protein synthesis, and tissue maintenance processes associated with growth hormone signalling. Its unique pharmacological design allows researchers to assess chronic endocrine stimulation, adaptive hormonal responses, and long-term GH receptor dynamics in controlled laboratory settings.
(Read More About CJC-1295+DAC In Our Article)

Technical Specifications

• Contents: 5mg CJC-1295 + DAC
• Form: Lyophilized powder
• Purity: >99% (HPLC Verified)
• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
• Peptide Length: 44 Amino-Acids
• pH Range: 4.5-7.0
• Storage: Store between 1°C and 3°C

Note: Reconstitute with 50% Bacteriostatic (BAC) water and 50% Acetic Acid for best results.

Related Research Compounds

Hexarelin 5mg
IGF-1 LR3 1mg
GHRP-6 10mg

Disclaimer

For research purposes only, Not for human consumption.